10-Q: CLS Holdings USA Reports Q3 2024 Results with Revenue Decline and Debt Restructuring

CLS Holdings USA experienced a revenue decrease in Q3 2024 compared to Q3 2023, while also undertaking significant debt restructuring efforts.

Summary

• CLS Holdings USA reported a revenue of $4.9 million for the three months ended February 29, 2024, a 9% decrease compared to the same period in 2023.
• The company's dispensary revenue decreased by 15%, while production revenue increased slightly by 1%.
• Cost of goods sold decreased by 3%, but gross margin also decreased to 43.2% from 47.2%.
• Selling, general, and administrative expenses increased by 7% due to professional fees related to refinancing.
• The company experienced a net loss of $4.3 million for the quarter, compared to a net loss of $1 million in the same period last year.
• Interest expense decreased by 62% due to debt repayments and settlements.
• The company restructured and redeemed certain convertible debentures, resulting in a net loss on extinguishment of debt of $4.4 million.
• For the nine months ended February 29, 2024, revenue was $15.2 million, a 13% decrease compared to the same period in 2023.
• The company's net loss for the nine months was $6.1 million, compared to a net loss of $10.5 million in the same period last year.
• The company has taken steps to improve liquidity and reduce debt, including private placements and debt conversions.
• The company's working capital deficit improved to $9.4 million from $11.7 million at the end of the previous fiscal year.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with significant revenue declines and net losses, but also highlights positive steps in debt restructuring and cost control. The overall sentiment is cautiously negative due to the financial challenges, but there are some positive signs of management action.

Positives

• The company's working capital deficit improved by $2.3 million.
• Cash flow from operating activities improved by $1.6 million for the nine months ended February 29, 2024.
• Interest expense decreased by 62% in Q3 2024 and 45% for the nine months ended February 29, 2024.
• The company has taken steps to reduce debt through restructuring and conversions.
• The company has generated positive cash flow from operating activities for the last four quarters, excluding the most recent quarter.

Negatives

• Revenue decreased by 9% in Q3 2024 and 13% for the nine months ended February 29, 2024.
• The company reported a net loss of $4.3 million in Q3 2024 and $6.1 million for the nine months ended February 29, 2024.
• Gross margin decreased to 43.2% in Q3 2024 from 47.2% in Q3 2023.
• Selling, general, and administrative expenses increased by 7% in Q3 2024.
• The company recorded a net loss on extinguishment of debt of $4.4 million in Q3 2024.
• Cash flow from operating activities fell to a negative $(415,781) for the three months ended February 29, 2024.

Risks

• The company's ability to continue as a going concern is dependent on generating profitable operations and obtaining necessary financing.
• The company faces risks associated with the cannabis industry, including regulatory changes and market competition.
• The company's operations are subject to Section 280E of the Internal Revenue Code, which limits deductions for cannabis businesses.
• The company has a significant tax liability under Section 280E, which is currently being expensed as a change in estimate.
• The company's operations are subject to the effects of climate change, which could impact crop quality and energy costs.

Future Outlook

The company expects revenue growth as operations expand and anticipates sufficient capital through internally generated cash, debt/equity sales, and debt conversions. However, the company acknowledges the risks and challenges of the cannabis industry.

Management Comments

• Management intends to finance operating costs over the next twelve months with revenues from operations.
• Management believes that the company will have sufficient capital to satisfy its obligations through the use of internally generated cash, the sale of debt and or equity, and the conversion of debt to equity.

Industry Context

The company operates in the cannabis industry, which is subject to evolving regulations and market dynamics. The company is attempting to create a gold standard national brand by standardizing the testing, compliance and labeling of its products in an industry currently comprised of small, local businesses with erratic and unreliable product quality, testing practices and labeling. The company is also attempting to grow through select acquisitions in secondary and tertiary markets, targeting newly regulated states that it believes offer a competitive advantage.

Comparison to Industry Standards

• The company's revenue decline of 9% in Q3 2024 and 13% for the nine months ended February 29, 2024, indicates a challenging period compared to the previous year, which may be reflective of broader market trends in the cannabis industry, including price compression and reduced consumer spending.
• The decrease in gross margin to 43.2% in Q3 2024 from 47.2% in Q3 2023 suggests increased competition or higher input costs, which is a common challenge in the cannabis sector.
• The company's net loss of $4.3 million in Q3 2024 and $6.1 million for the nine months ended February 29, 2024, highlights the financial pressures faced by many cannabis companies, particularly those in the growth phase.
• The company's debt restructuring efforts, including the conversion of debentures into equity, are a common strategy in the cannabis industry to manage financial obligations and improve balance sheets, similar to actions taken by companies like Canopy Growth and Aurora Cannabis.
• The company's focus on cost control and operational efficiency, as evidenced by the decrease in SG&A expenses, is a necessary step for cannabis companies to achieve profitability, similar to strategies employed by companies like Curaleaf and Trulieve.
• The company's efforts to improve liquidity and reduce debt are crucial for long-term sustainability, which is a common goal for cannabis companies facing financial challenges, similar to actions taken by companies like Tilray and Organigram.

Legal Proceedings

• The company reached agreements with Integrity Global Security Inc. to settle a breach of contract claim for $45,000 net cost.

Related Party Transactions

• The company accrued interest in the amount of $110,066 on a convertible note payable to Navy Capital Green Co-Invest Fund, LLC, an entity that holds greater than 10% of the company's common stock outstanding.
• The company made payments of $10,000 to each of its three directors for their participation on the Board, for a total of $30,000.
• The company's Board of Directors authorized a bonus for its Chief Executive Officer in the amount of $50,000.

Stakeholder Impact

• Shareholders may be concerned about the company's revenue decline and net losses.
• Employees may be affected by cost-cutting measures and potential restructuring.
• Customers may experience changes in product offerings or service levels.
• Suppliers may be impacted by the company's financial performance and payment terms.
• Creditors may be affected by the company's debt restructuring efforts.

Next Steps

• The company will continue to explore opportunities for growth through acquisitions, joint ventures, licensing agreements, and fee-for-service arrangements.
• The company will continue to focus on cost control and operational efficiency.
• The company will continue to manage its debt through restructuring and conversions.

Key Dates

Keywords

cannabis, dispensary, extraction, debt restructuring, financial results, revenue, net loss, operating expenses, convertible debentures, going concern